Financial Performance - The company reported a net loss of $125.3 million for the three months ended March 31, 2024, compared to a net income of $48.7 million for the same period in 2023, marking a significant decline [88]. - Total revenue for the three months ended March 31, 2024, decreased by $146.3 million or 100.0% from the same period in 2023, primarily due to decreased revenue recognition from license and collaboration agreements [93]. - The company recorded a net loss per share – diluted of $1.02 for the three months ended March 31, 2024, compared to net income per share – diluted of $0.45 for the same period in 2023 [92]. Cash and Assets - The company had $127.7 million in cash, cash equivalents, and restricted cash as of March 31, 2024, an increase from $110.9 million as of September 30, 2023 [89]. - The company had total assets of $955.2 million as of March 31, 2024, compared to $765.6 million as of September 30, 2023 [89]. - Cash, cash equivalents, and restricted cash at the end of the period totaled $127.7 million as of March 31, 2024, compared to $135.0 million at the end of March 31, 2023 [108]. - The net increase in cash, cash equivalents, and restricted cash for the six months ended March 31, 2024, was $16.7 million, down from $27.2 million in the prior year [108]. Research and Development - Research and development expenses increased as the company's pipeline of candidates expanded and progressed through clinical trial phases [88]. - Total research and development expense was $101.1 million for the three months ended March 31, 2024, up from $74.9 million for the same period in 2023, representing a 35% increase [102]. - Candidate costs increased by $7.3 million, or 28%, for the three months ended March 31, 2024, and $10.3 million, or 15%, for the six months ended March 31, 2024 compared to the same period of 2023 [98]. - R&D discovery costs rose by $7.4 million, or 42%, for the three months ended March 31, 2024, and $23.9 million, or 79%, for the six months ended March 31, 2024 compared to the same period of 2023 [99]. - The company continues to develop other clinical candidates for future trials, with candidate costs expected to increase as development progresses [88]. - The company initiated a Phase 1/2a clinical trial of ARO-DM1 for type 1 myotonic dystrophy and filed for clearance to initiate a Phase 1/2a trial of ARO-CFB for complement-mediated renal disease [88]. Expenses - General and administrative expenses totaled $25.1 million for the three months ended March 31, 2024, an increase of $1.8 million, or 8%, compared to $23.2 million for the same period in 2023 [101]. - Salaries increased by $8.5 million, or 52%, for the three months ended March 31, 2024, and $16.4 million, or 53%, for the six months ended March 31, 2024 compared to the same period in 2023 [99]. - Facilities-related expenses increased by $2.5 million, or 72%, for the three months ended March 31, 2024, compared to the same period of 2023 [99]. - Depreciation and amortization expense increased by $1.8 million, or 81%, for the three months ended March 31, 2024, compared to the same period of 2023 [99]. - Other expense increased by $0.3 million and $2.8 million for the three and six months ended March 31, 2024, respectively, compared to the same periods of 2023 [105]. Cash Flow - Cash flow used in operating activities for the six months ended March 31, 2024, was $210.2 million, compared to $107.2 million for the same period in 2023, reflecting increased ongoing expenses related to research and development and administrative costs [108]. - Cash used in investing activities amounted to $204.1 million for the six months ended March 31, 2024, primarily due to capital expenditures of $102.7 million and investment purchases of $310.0 million, offset by proceeds from sales and maturities of investments of $208.6 million [108]. - Cash provided by financing activities was $431.0 million for the six months ended March 31, 2024, mainly from the issuance of common stock and stock option exercises, compared to $251.1 million in the same period in 2023 [108]. Other Information - The company completed enrollment in Amgen's Phase 3 OCEAN trial of olpasiran, triggering a $50.0 million milestone payment, which was received in Q3 of fiscal 2024 [88]. - There has been no material change in the Company's contractual obligations from the previous reporting period [109]. - The Company's exposure to market risk has not materially changed from the previous reporting period [110].

Core Viewpoint - The technology sector may face a slowdown, prompting a potential shift towards biotech stocks, which have not received the same attention despite their innovation potential [1] Group 1: Crispr Therapeutics (CRSP) - Crispr Therapeutics is utilizing the CRISPR gene-editing platform to develop medicines, with expected revenue of $105.82 million in fiscal 2024, down 71.5% from $371.21 million in 2023, but projected to rise to $405.2 million by 2025, a 9.2% increase from 2023 [2] - The gene editing market is anticipated to reach $15.8 billion by 2031, up from a valuation of $1.89 billion in 2022 [2] Group 2: Halozyme (HALO) - Halozyme develops oncology therapies and has seen its stock gain over 12% since the start of the year, with expected revenue of $954.58 million for the current fiscal year, a 15.1% increase from $829.25 million last year [5] - Analysts project earnings per share (EPS) of $3.68 for this year, up from $2.77 in 2023, with a forecast of $4.58 for 2025 [5] Group 3: SpringWorks Therapeutics (SWTX) - SpringWorks focuses on targeted oncology and is expected to achieve revenue of $87.34 million this fiscal year, a 1,503.5% increase from $5.45 million last year, with projections of $256.3 million in 2025 [7] - Analysts rate shares a unanimous strong buy with an average price target of $66.33, implying a 33% increase [8] Group 4: Cytokinetics (CYTK) - Cytokinetics develops muscle activators and inhibitors, with projected sales of $6.57 million this year, a 12.7% decline from $7.53 million last year, but expected to rise to $146.24 million by 2025, a 2,126% increase from 2024 [9] - Analysts rate shares a strong buy with an average price target of $94.63, indicating nearly 47% growth potential [10] Group 5: Jazz Pharmaceuticals (JAZZ) - Jazz Pharmaceuticals, known for its product Xyrem, is expected to report revenue of $4.11 billion for the current fiscal year, a 7.2% increase from $3.83 billion last year, with projections of $4.4 billion in 2025 [11] - Analysts rate shares a strong buy with a forecast price of $183.82, suggesting almost 59% upside potential [12] Group 6: Viking Therapeutics (VKTX) - Viking Therapeutics has gained 267% in equity value since January, focusing on therapeutics for metabolic disorders, although no sales forecast is provided [13] - Analysts unanimously rate VKTX a strong buy with an average price target of $102.43, implying nearly 53% upside potential [14] Group 7: Arrowhead Pharmaceuticals (ARWR) - Arrowhead Pharmaceuticals specializes in RNA-based therapeutics, with expected sales of $139 million this fiscal year, a 42.2% decline from $240.74 million last year, but projected to reach $157.94 million in 2025 [15] - The consensus view for ARWR stock is a moderate buy, with an average price target of $53.70, indicating 88% upside potential [16]

Core Viewpoint - The Russell 2000 Index is expected to perform well in 2024, with a projected return of about 9% in the first half and 15% over the next 12 months, driven by low valuations and an improving economic outlook [1]. Group 1: Russell 2000 Performance - The Russell 2000 Index closed 2023 with a 15.1% gain and is up approximately 4% year to date as of January 2, 2024 [1]. - Small-cap stocks within the Russell 2000 are currently trading at low valuations compared to historical levels, which is expected to drive returns [1]. Group 2: Arrowhead Pharmaceuticals (ARWR) - Arrowhead Pharmaceuticals has seen its stock price increase from $28.53 to $33.45, with potential for further growth due to speculation of being an acquisition target and ongoing development of 14 investigational medicines [2][3]. - The global drug development market is projected to reach $181.4 billion by 2032, which could significantly benefit Arrowhead, currently valued at $4.14 billion [3]. Group 3: Murphy Oil (MUR) - Murphy Oil's stock price has risen from around $39 to $41.12, with expectations for it to reach $44 and potentially $48 [5][6]. - The company has generated substantial free cash flow, returning about $150 million to shareholders through buybacks and retiring $500 million of debt [5][6]. Group 4: Duolingo Inc. (DUOL) - Duolingo's stock price increased from $177 to a high of $241.86, with a recent pullback to $213.53, but is expected to push higher [7]. - The company reported a fourth-quarter EPS of 26 cents, beating estimates by 10 cents, and revenue increased by 45.4% year over year [8]. - Daily active subscriptions surged to 26.9 million, a 65% increase quarter over quarter, indicating strong growth potential [8].

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dose-escalating study (NCT06138743) to evaluate single and multiple ascending doses of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic, in up to 48 subjects with type 1 myotonic dystrophy (DM1). DM1 is the most common adult-onset muscular dystrophy. Patients with DM1 have muscle weakness and wast ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual Health Care Conference – March 6, 2024 Type: Fireside Chat Presentation Date: March 6, 2024 Time: 9:10 a.m. ET Leerink Partners Global Biopharma Conference – March 13, 2024 Type: Fireside Chat Presentation Date: March 13, 2024 Time: 8:00 a.m. ET Presentation materials may be accessed on the Events and Presentations ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38042 _____________________________________ ARROWHEAD ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal first quarter ended December 31, 2023. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of ...

icarus666/Moment via Getty Images In my coverage of Arrowhead Pharmaceuticals (ARWR) last February, I noted that my primary problem with ARWR is a lack of focus. Just look at this pipeline: ARWR PIPELINE (ARWR WEBSITE) There are, if I am counting it right, some 16 programs in the clinic, and frankly, this is too much. Like I noted last time, they should probably have focused on getting one product through the finishing line. Then, this long-tailed pipeline would have been an asset. If you want a good tail, ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Conference Call November 29, 2023 4:30 PM ET Company Participants Vince Anzalone - Vice President, Investor Relations Chris Anzalone - President & Chief Executive Officer Javier San Martin - Chief Medical Officer James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - Chief Financial Officer Tracy Oliver - Chief Commercial Officer Patrick O'Brien - Chief Operating Officer and General Counsel Conference Call Participants Edward ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-K __________________________________________________________________ (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38042 ________ ...